Crispr Therapeutics Ag Stock Net Asset
| CRSP Stock | USD 41.58 0.22 0.53% |
Crispr Therapeutics' fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Crispr Stock price.
Crispr | Net Asset | Build AI portfolio with Crispr Stock |
Crispr Therapeutics AG Company Net Asset Analysis
Crispr Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Crispr Therapeutics Net Asset | 2.24 B |
Most of Crispr Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Crispr Therapeutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Crispr Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Crispr Therapeutics is extremely important. It helps to project a fair market value of Crispr Stock properly, considering its historical fundamentals such as Net Asset. Since Crispr Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Crispr Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Crispr Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Crispr Total Assets
Total Assets |
|
Based on the recorded statements, Crispr Therapeutics AG has a Net Asset of 2.24 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Crispr Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Crispr Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Crispr Therapeutics could also be used in its relative valuation, which is a method of valuing Crispr Therapeutics by comparing valuation metrics of similar companies.Crispr Therapeutics is currently under evaluation in net asset category among its peers.
Crispr Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Crispr Therapeutics from analyzing Crispr Therapeutics' financial statements. These drivers represent accounts that assess Crispr Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Crispr Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 10.1B | 5.8B | 3.2B | 3.3B | 3.0B | 2.3B | |
| Enterprise Value | 9.0B | 5.1B | 3.2B | 3.2B | 2.9B | 2.0B |
Crispr Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Crispr Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Crispr Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Crispr Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Crispr Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Crispr Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Crispr Therapeutics' value.| Shares | Nea Management Company, Llc | 2025-03-31 | 1.6 M | Orbis Allan Gray Ltd | 2025-03-31 | 1.6 M | Ecor1 Capital, Llc | 2025-03-31 | 1.4 M | Bank Of America Corp | 2025-03-31 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 1.3 M | Two Sigma Investments Llc | 2025-03-31 | 1.2 M | Sr One Capital Management, Lp | 2025-03-31 | 1 M | Geode Capital Management, Llc | 2025-03-31 | 1 M | Dimensional Fund Advisors, Inc. | 2025-03-31 | 937.1 K | Ark Investment Management Llc | 2025-03-31 | 10.2 M | Capital Research & Mgmt Co - Division 3 | 2025-03-31 | 6.1 M |
Crispr Fundamentals
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (171.59) % | ||||
| Current Valuation | 1.96 B | ||||
| Shares Outstanding | 86.36 M | ||||
| Shares Owned By Insiders | 1.70 % | ||||
| Shares Owned By Institutions | 76.57 % | ||||
| Number Of Shares Shorted | 20.54 M | ||||
| Price To Earning | 17.33 X | ||||
| Price To Book | 1.95 X | ||||
| Price To Sales | 94.81 X | ||||
| Revenue | 35 M | ||||
| Gross Profit | (400.08 M) | ||||
| EBITDA | (447.31 M) | ||||
| Net Income | (366.25 M) | ||||
| Cash And Equivalents | 2.07 B | ||||
| Cash Per Share | 26.48 X | ||||
| Total Debt | 223.69 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 17.57 X | ||||
| Book Value Per Share | 21.18 X | ||||
| Cash Flow From Operations | (142.77 M) | ||||
| Short Ratio | 9.98 X | ||||
| Earnings Per Share | (4.49) X | ||||
| Price To Earnings To Growth | (0.21) X | ||||
| Target Price | 81.67 | ||||
| Number Of Employees | 393 | ||||
| Beta | 1.74 | ||||
| Market Capitalization | 3.59 B | ||||
| Total Asset | 2.24 B | ||||
| Retained Earnings | (1.37 B) | ||||
| Working Capital | 1.85 B | ||||
| Current Asset | 232 M | ||||
| Current Liabilities | 78 M | ||||
| Net Asset | 2.24 B |
About Crispr Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Crispr Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Crispr Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Crispr Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Crispr Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crispr Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Crispr Stock
The ability to find closely correlated positions to Crispr Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crispr Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crispr Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crispr Therapeutics AG to buy it.
The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crispr Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crispr Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crispr Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.